How Biotech Freed Itself From FDA Shackles: Trevena’s 108.72% Stock Rise

October 9, 2018
This article was written by Graham Ellinson, a Financial Analyst at I Know First currently studying Mathematics at Northumbria University Newcastle.  

 Source: logosandbrands.directory

Highlights

      • OLINVO and other pipeline products drive TRVN growth
      • The rate of FDA drug approval has risen significantly across the board over the last year
      • I Know First algorithm is currently bullish on TRVN

        • premiumRead The Full Premium Article

        Subscribe to receive exclusive PREMIUM content Here
Biotech Stocks Forecast Healthcare Premium Articles

Regeneron Stock Forecast: Bullish Long Term Buy For This Undervalued Stock

July 1, 2018

 

This article was written by Grant Goldstein, a Financial Analyst at I Know First

   

Highlights:

  • Regeneron has Underwhelming Q1 Financials
  • REGN is Undervalued
  • I Know First Bullish Forecast for REGN
I Know First.  

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here
Biotech Stocks Forecast Healthcare Premium Articles